SCHEDULE 13G: Intracoastal Capital and Affiliates Report 0% Beneficial Ownership in Aptevo Therapeutics Following Share Issuance

Intracoastal Capital LLC, Mitchell P. Kopin, and Daniel B. Asher have reported a 0.00% beneficial ownership stake in Aptevo Therapeutics Inc. as of June 25, 2025, down from approximately 9.8% on June 18, 2025, due to a significant share issuance by the company.

Summary

• Reporting Persons: Mitchell P. Kopin, Daniel B. Asher, and Intracoastal Capital LLC.
• Issuer: Aptevo Therapeutics Inc., with its principal executive offices located at 2401 4th Avenue, Suite 1050, Seattle, Washington 98121.
• Securities: Common stock, par value $0.001 per share, with CUSIP No. 03835L405.
• Initial Beneficial Ownership (June 18, 2025): Immediately following the execution of the Securities Purchase Agreement (SPA), the Reporting Persons were deemed to have beneficial ownership of 82,000 shares of Common Stock, representing approximately 9.8% of the Common Stock. This was based on 759,156 shares outstanding as of June 18, 2025, plus the 82,000 shares to be issued to Intracoastal at the closing of the SPA.
• Current Beneficial Ownership (June 25, 2025): As of the close of business on June 25, 2025, the Reporting Persons were deemed to have beneficial ownership of 0 shares of Common Stock, representing approximately 0.00% of the Common Stock. This calculation is based on 759,156 shares outstanding as of June 18, 2025, plus 2,105,000 shares of Common Stock issued at the closing of the transaction contemplated by the SPA.
• Warrant Exclusions: The beneficial ownership calculation excludes 410,000 shares issuable upon exercise of Intracoastal Warrant 1 and 15,500 shares issuable upon exercise of Intracoastal Warrant 2. These warrants are not exercisable until the effective date of stockholder approval of the issuance of the underlying shares and contain blocker provisions limiting beneficial ownership to 9.99%.
• Purpose of Holding: The Reporting Persons certify that the securities were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer.

Sentiment

Score: 4

Explanation: The filing itself is a factual disclosure of a change in beneficial ownership, which has decreased to 0% for the reporting persons due to significant share issuance by the issuer. While the filing is neutral in tone, the underlying event (substantial share issuance) implies dilution for existing shareholders, which is generally viewed negatively. However, the capital raise itself could be positive for the company's operations.

Positives

• The document provides clear and detailed disclosure regarding the change in beneficial ownership and the underlying transactions.
• The Reporting Persons explicitly state their passive investment intent, confirming they are not seeking to influence control of the issuer.

Negatives

• The significant dilution of the Reporting Persons' stake from approximately 9.8% to 0.00% indicates a substantial issuance of new shares by Aptevo Therapeutics Inc., which could dilute the ownership percentage of existing shareholders.

Risks

• Potential future dilution for existing shareholders if the warrants (Intracoastal Warrant 1 for 410,000 shares and Intracoastal Warrant 2 for 15,500 shares) are exercised, pending stockholder approval.
• The blocker provisions on the warrants limit immediate exercisability, but their future exercise could still impact the total share count and per-share value.

Future Outlook

NA

Management Comments

• The undersigned acknowledge and agree that the foregoing statement on Schedule 13G is filed on behalf of each of the undersigned and that all subsequent amendments to this statement on Schedule 13G may be filed on behalf of each of the undersigned without the necessity of filing additional joint filing agreements.
• The undersigned acknowledge that each shall be responsible for the timely filing of such amendments, and for the completeness and accuracy of the information concerning him or it contained herein and therein, but shall not be responsible for the completeness and accuracy of the information concerning the others, except to the extent that he or it knows or has reason to believe that such information is inaccurate.
• By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.

Industry Context

This filing is a standard regulatory disclosure of a change in passive beneficial ownership. It does not provide broader industry trends or competitive analysis. The dilution of the reporting persons' stake suggests Aptevo Therapeutics Inc. may have recently raised capital, which is a common activity for companies, particularly in the biotech/pharma industry, to fund research and development or general operations.

Stakeholder Impact

• Shareholders: Existing shareholders face significant dilution due to the issuance of 2,105,000 new shares, which reduced the percentage ownership of the reporting persons. Future dilution is possible if warrants are exercised.

Next Steps

• Stockholder approval is required for the exercise of Intracoastal Warrant 1 (410,000 shares) and Intracoastal Warrant 2 (15,500 shares).

Key Dates

Keywords

Aptevo Therapeutics Inc., Schedule 13G, beneficial ownership, common stock, share dilution, Securities Purchase Agreement, warrants, Mitchell P. Kopin, Daniel B. Asher, Intracoastal Capital LLC, SEC filing